However, continuous subcutaneous insulin infusion (CSII) therapy using an insulin pump has been shown to provide precise insulin delivery, improved glycemic outcomes, and reduced risk of hypoglycemia, making it an increasingly popular option for patients with T1DM [2-4]. This evidence concerns the gene INS and Hypoglycemia.